collection
MENU ▼
Read by QxMD icon Read
search

Rheumatoid Arthritis

shared collection
117 papers 25 to 100 followers
https://www.readbyqxmd.com/read/28283528/rheumatoid-arthritis-phenotype-at-presentation-differs-depending-on-the-number-of-autoantibodies-present
#1
V F A M Derksen, S Ajeganova, L A Trouw, A H M van der Helm-van Mil, I Hafström, T W J Huizinga, R E M Toes, B Svensson, D van der Woude
OBJECTIVES: In rheumatoid arthritis (RA), seropositive and seronegative disease may be two entities with different underlying pathophysiological mechanisms, long-term outcomes and disease presentations. However, the effect of the conjoint presence of multiple autoantibodies, as proxy for a more pronounced humoral autoimmune response, on clinical phenotype remains unclear. Therefore, this study investigates the association between the number of autoantibodies and initial clinical presentation in two independent cohorts of patients with early RA...
April 2016: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28422773/infections-in-rheumatoid-arthritis
#2
Fabiola Atzeni, Ignazio Francesco Masala, Manuela di Franco, Piercarlo Sarzi-Puttini
PURPOSE OF REVIEW: The purpose of this review is to provide an update concerning recent advances in the evidence- based study of serious infections in patients with rheumatoid arthritis (RA) treated with biological drugs or conventional disease-modifying antirheumatic drugs (DMARDs), concentrating on studies published in the last 18 months. RECENT FINDINGS: New studies have further strengthened existing evidence relating the use of biological drugs to serious infections...
April 18, 2017: Current Opinion in Rheumatology
https://www.readbyqxmd.com/read/28199724/cardiovascular-risk-management-in-rheumatoid-arthritis-patients-still-suboptimal-the-implementation-of-cardiovascular-risk-management-in-rheumatoid-arthritis-project
#3
Inge A M van den Oever, Maaike Heslinga, Ed N Griep, Hanneke R M Griep-Wentink, Rob Schotsman, Walter Cambach, Ben A C Dijkmans, Yvo M Smulders, Willem F Lems, Maarten Boers, Alexandre E Voskuyl, Mike J L Peters, Dirkjan van Schaardenburg, Micheal T Nurmohamed
No abstract text is available yet for this article.
February 10, 2017: Rheumatology
https://www.readbyqxmd.com/read/28339817/bsr-and-bhpr-guideline-for-the-prescription-and-monitoring-of-non-biologic-disease-modifying-anti-rheumatic-drugs
#4
Jo Ledingham, Nicola Gullick, Katherine Irving, Rachel Gorodkin, Melissa Aris, Jean Burke, Patrick Gordon, Dimitrios Christidis, Sarah Galloway, Eranga Hayes, Andrew Jeffries, Scott Mercer, Janice Mooney, Sander van Leuven, James Galloway
No abstract text is available yet for this article.
February 27, 2017: Rheumatology
https://www.readbyqxmd.com/read/28339992/rheumatoid-arthritis-specific-cardiovascular-risk-scores-are-not-superior-to-general-risk-scores-a-validation-analysis-of-patients-from-seven-countries
#5
Cynthia S Crowson, Sherine E Gabriel, Anne Grete Semb, Piet L C M van Riel, George Karpouzas, Patrick H Dessein, Carol Hitchon, Virginia Pascual-Ramos, George D Kitas
Objectives.: Cardiovascular disease (CVD) risk calculators developed for the general population do not accurately predict CVD events in patients with RA. We sought to externally validate risk calculators recommended for use in patients with RA including the EULAR 1.5 multiplier, the Expanded Cardiovascular Risk Prediction Score for RA (ERS-RA) and QRISK2. Methods.: Seven RA cohorts from UK, Norway, Netherlands, USA, South Africa, Canada and Mexico were combined...
March 8, 2017: Rheumatology
https://www.readbyqxmd.com/read/28371899/cardiovascular-risk-management-in-rheumatoid-arthritis-challenges-ahead-barriers-in-the-implementation-of-cardiovascular-risk-management-for-rheumatoid-arthritis-patients-in-daily-practice
#6
https://www.readbyqxmd.com/read/28407099/discontinuation-of-tofacitinib-after-achieving-low-disease-activity-in-patients-with-rheumatoid-arthritis-a-multicentre-observational-study
#7
Satoshi Kubo, Kunihiro Yamaoka, Koichi Amano, Shuji Nagano, Shigeto Tohma, Eiichi Suematsu, Hayato Nagasawa, Kanako Iwata, Yoshiya Tanaka
Objective.: To determine whether tofacitinib can be discontinued in patients with RA who achieve low disease activity (LDA). Methods.: RA patients with LDA after tofacitinib treatment in a phase III and long-term extension study were enrolled in this multicentre, non-randomized, open, prospective, observational study. The decision of discontinuation or continuation of tofacitinib was determined based on patient-physician decision making with informed consent. The primary endpoint was the proportion of patients who remained tofacitinib-free at post-treatment week 52...
April 12, 2017: Rheumatology
https://www.readbyqxmd.com/read/28425173/the-20-year-outcome-and-association-between-early-treatment-and-mortality-and-disability-in-an-inception-cohort-of-patients-with-rheumatoid-arthritis-results-from-the-norfolk-arthritis-register
#8
James M Gwinnutt, Deborah Pm Symmons, Alexander J MacGregor, Jacqueline R Chipping, Tarnya Marshall, Mark Lunt, Suzanne Mm Verstappen
Objective - To describe the outcome of patients with rheumatoid arthritis (RA) over 20 years from symptom onset; to assess the association between early treatment (DMARDs/steroids) and mortality and disability over follow-up. Methods - Patients from the Norfolk Arthritis Register recruited from 1990-94 who met the 2010 ACR/EULAR RA criteria at baseline were included in this analysis. Demographic/clinical variables were collected at baseline and years 1-3, 5, 7, 10, 15 and 20. Disease activity (swollen/tender joint counts (SJC/TJC)), disability (HAQ) and mortality over 20 years are described...
April 20, 2017: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/28411169/the-impact-of-immunogenicity-of-tnf%C3%AE-inhibitors-in-autoimmune-inflammatory-disease-a-systematic-review-and-meta-analysis
#9
REVIEW
Valentina Pecoraro, Elena De Santis, Alessandra Melegari, Tommaso Trenti
BACKGROUND: Monoclonal antibodies drugs directed against TNFα, TNFα inhibitors, are immunogenic, and consequent anti-drug antibodies (ADA) formation may decrease the functional drug concentration, resulting in a loss of response. We evaluated the impact of ADA on TNFα therapeutic response. METHODS: We considered studies enrolling adult patients affected by autoimmune inflammatory disease in therapy with TNFα inhibitors. We collected data about study and population characteristics, treatment dosage, determination of ADA and adverse events (AE)...
April 11, 2017: Autoimmunity Reviews
https://www.readbyqxmd.com/read/28371512/cognitive-impairment-in-rheumatoid-arthritis-a-systematic-review
#10
Tanya Meade, Nicholas Manolios, Steven R Cumming, Philip G Conaghan, Patricia Katz
OBJECTIVES: Rheumatoid Arthritis (RA) is not commonly associated with central nervous system and brain changes. However a number of studies have reported high rates of cognitive impairment (CI) in adults with RA. The objective of this systematic review was to identify and explore the rates and types of CI in RA. METHODS: Multiple databases were searched including a time frame between 1994 to 2016 to identify studies that have included: (i) adults with RA; (ii) standardized neuropsychological tests; and (iii) sufficient information to ascertain the relationship between CI and demographic, clinical and psychology factors...
March 28, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/28388820/rheumatoid-arthritis-treatment-after-methotrexate-triple-therapy-is-more-durable-than-etanercept
#11
Shana M Peper, Robert Lew, Ted Mikuls, Mary Brophy, Denis Rybin, Hongseng Wu, James O'Dell
OBJECTIVE: Although it is common for rheumatologists to initiate biologics after failure of methotrexate monotherapy in rheumatoid arthritis (RA), ample data supports the initial use of combinations of conventional therapies in this clinical scenario. Our study explores the durability of triple therapy (methotrexate, sulfasalazine, and hydroxychloroquine) versus methotrexate-etanercept in RA. METHODS: RA patients with suboptimal response to methotrexate (n = 353) were randomized to either triple therapy or methotrexate-etanercept therapy in a 48-week, double-blinded, non-inferiority trial...
April 7, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/28389552/tocilizumab-combination-therapy-or-monotherapy-or-methotrexate-monotherapy-in-methotrexate-naive-patients-with-early-rheumatoid-arthritis-2-year-clinical-and-radiographic-results-from-the-randomised-placebo-controlled-function-trial
#12
Gerd R Burmester, William F Rigby, Ronald F van Vollenhoven, Jonathan Kay, Andrea Rubbert-Roth, Ricardo Blanco, Alysha Kadva, Sophie Dimonaco
OBJECTIVE: Investigate whether the efficacy and safety of intravenous tocilizumab (TCZ) demonstrated at week 52 in patients with early rheumatoid arthritis (RA) are maintained to week 104. METHODS: Methotrexate (MTX)-naive patients with early progressive RA were randomly assigned to double-blind 4 mg/kg TCZ+MTX, 8 mg/kg TCZ+MTX, 8 mg/kg TCZ+placebo or placebo+MTX for 104 weeks. Patients not receiving 8 mg/kg TCZ and not achieving Disease Activity Score-28 joints (DAS28-erythrocyte sedimentation rate (ESR)) ≤3...
April 7, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28385457/clinical-meaning-and-implications-of-serum-hemoglobin-levels-in-patients-with-rheumatoid-arthritis
#13
Ivan Padjen, Leopold Öhler, Paul Studenic, Thasia Woodworth, Josef Smolen, Daniel Aletaha
OBJECTIVE: Anemia is a common problem in rheumatoid arthritis (RA), associated with radiographic progression and disability. We explored the association of hemoglobin with a comprehensive set of variables in RA patients. METHODS: We included RA outpatients in the routine setting. For each patient we performed measurements (clinical measures, blood tests including serology, markers of acute phase response and iron metabolism, including hepcidin, and circulating hematopoietic precursor levels) at baseline and 12 weeks thereafter, and analyzed their changes in patients with a treatment adaptation at baseline...
March 8, 2017: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/27607196/clinical-radiographic-and-functional-efficacy-of-abatacept-in-routine-care-for-rheumatoid-arthritis-patients-abatacept-leading-trial-for-ra-on-imaging-remission-altair-study
#14
Satoshi Kubo, Kazuhisa Nakano, Shingo Nakayamada, Shintaro Hirata, Shunsuke Fukuyo, Norifumi Sawamukai, Kazuyoshi Saito, Yoshiya Tanaka
OBJECTIVES: To investigate the efficacy and safety of abatacept for treating patients with rheumatoid arthritis (RA) in routine clinical practice and to determine the prognostic factors affecting clinical outcomes. METHODS: We performed a retrospective study of 194 RA patients treated with abatacept. Clinical outcomes at 1 year after the treatment were assessed. Joint damage was assessed by the van der Heijde-modified total Sharp score (mTSS). RESULTS: Of the 194 patients, abatacept was discontinued in 51 patients, resulting in a retention rate at week 52 of 73...
September 2016: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28279855/anti-therapeutic-antibodies-and-their-clinical-impact-in-patients-treated-with-the-tnf-antagonist-adalimumab
#15
Isabelle Cludts, Francesca Romana Spinelli, Francesca Morello, Jason Hockley, Guido Valesini, Meenu Wadhwa
Patients treated with the TNF antagonist adalimumab develop anti-therapeutic antibodies (ATA), the prevalence of which varies depending on the assay used. Most assays are compromised due to the presence of adalimumab in the clinical samples. Our objective was to develop an antibody assay, applicable for clinical testing, which overcomes the limitation of therapeutic interference and to further determine the relationship between ATA development, adalimumab levels and disease activity in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) or ankylosing spondylitis (AS)...
March 6, 2017: Cytokine
https://www.readbyqxmd.com/read/28326189/sarilumab-improves-patient-reported-outcomes-in-rheumatoid-arthritis-patients-with-inadequate-response-intolerance-to-tumour-necrosis-factor-inhibitors
#16
Vibeke Strand, Matthew Reaney, Chieh-I Chen, Clare W J Proudfoot, Sophie Guillonneau, Deborah Bauer, Erin Mangan, Neil M H Graham, Hubert van Hoogstraten, Yong Lin, César Pacheco-Tena, Roy Fleischmann
OBJECTIVE: To evaluate effects of the anti-interleukin-6 receptor monoclonal antibody sarilumab administered with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) on patient-reported outcomes (PROs) in the TARGET trial in patients with rheumatoid arthritis (RA) with inadequate response or intolerance to tumour necrosis factor inhibitors (TNF-IR). METHODS: 546 patients (81.9% female, mean age 52.9 years) were randomised to placebo, sarilumab 150 or 200 mg subcutaneously every 2 weeks + csDMARDs...
2017: RMD Open
https://www.readbyqxmd.com/read/28377787/tofacitinib-versus-biologic-treatments-in-moderate-to-severe-rheumatoid-arthritis-patients-who-have-had-an-inadequate-response-to-nonbiologic-dmards-systematic-literature-review-and-network-meta-analysis
#17
REVIEW
Evelien Bergrath, Robert A Gerber, David Gruben, Tatjana Lukic, Charles Makin, Gene Wallenstein
Objective. To compare the efficacy and tolerability of tofacitinib, an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA), as monotherapy and combined with disease-modifying antirheumatic drugs (DMARDs) versus biological DMARDs (bDMARDs) and other novel DMARDs for second-line moderate-to-severe rheumatoid arthritis (RA) patients by means of a systematic literature review (SLR) and network meta-analysis (NMA). Methods. MEDLINE®, EMBASE®, and Cochrane Central Register of Controlled Trials were searched to identify randomized clinical trials (RCTs) published between 1990 and March 2015...
2017: International Journal of Rheumatology
https://www.readbyqxmd.com/read/28284845/risks-of-malignancies-related-to-tofacitinib-and-biological-drugs-in-rheumatoid-arthritis-systematic-review-meta-analysis-and-network-meta-analysis
#18
José Ramón Maneiro, Alejandro Souto, Juan J Gomez-Reino
OBJECTIVE: To summarize and compare the risks of malignancies accompanying biologic DMARDs (b-DMARDs) and tofacitinib in rheumatoid arthritis (RA) in randomized clinical trials (RCTs) and long-term extension studies (LTEs). METHODS: Articles in Medline, Embase, Cochrane Library, and the Web of Science dated from 2000 to February 2015. Selection criteria were as follows: (1) focus on RCTs or LTEs in RA; (2) treatment with b-DMARDs or tofacitinib; (3) data on malignancies; and (4) a minimum follow-up of 12 weeks...
February 16, 2017: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/28360422/immunometabolism-in-early-and-late-stages-of-rheumatoid-arthritis
#19
REVIEW
Cornelia M Weyand, Jörg J Goronzy
One of the fundamental traits of immune cells in rheumatoid arthritis (RA) is their ability to proliferate, a property shared with the joint-resident cells that form the synovial pannus. The building of biomass imposes high demands for energy and biosynthetic precursors, implicating metabolic control as a basic disease mechanism. During preclinical RA, when autoreactive T cells expand and immunological tolerance is broken, the main sites of disease are the secondary lymphoid tissues. Naive CD4(+) T cells from patients with RA have a distinct metabolic signature, characterized by dampened glycolysis, low ATP levels and enhanced shunting of glucose into the pentose phosphate pathway...
March 31, 2017: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/28320445/risk-factors-for-flare-and-treatment-of-disease-flares-during-pregnancy-in-rheumatoid-arthritis-and-axial-spondyloarthritis-patients
#20
Stephanie van den Brandt, Astrid Zbinden, Dominique Baeten, Peter M Villiger, Monika Østensen, Frauke Förger
BACKGROUND: During pregnancy, patients with rheumatoid arthritis (RA) and axial spondyloarthritis (axSpA) can experience active disease, which might be influenced by adjustment of treatment around conception. The aim of this study was to identify possible risk factors of disease flares during pregnancy and to evaluate the effect of treatment in pregnant patients experiencing a flare. METHODS: Pregnant patients with RA and axSpA were prospectively followed before, during, and after pregnancy...
March 20, 2017: Arthritis Research & Therapy
label_collection
label_collection
7634
1
2
2017-03-31 02:33:12
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"